Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARDELYX, INC.ARDX · Entity 4972 | Chief Patient Officer | August 21, 2026 | August 25, 2026 |
| Enliven Therapeutics, Inc.IMRA · Entity 4024 | Director | June 02, 2022 | June 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARDELYX, INC.
Report date August 21, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 367,456 |
Ending reported balance
After 2026-08-21 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-21 · Sale · Disposed 3,486 · Balance 374,709 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 2 · 2026-08-21 · Sale · Disposed 3,089 · Balance 371,620 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 3 · 2026-08-21 · Sale · Disposed 2,430 · Balance 369,190 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 4 · 2026-08-21 · Sale · Disposed 1,734 · Balance 367,456 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Enliven Therapeutics, Inc.
Report date June 02, 2022 · Filed June 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2032-06-01 | Direct | 8,500 |
Reported balance
After 2022-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-02 · Grant · Acquired 8,500 · Balance 8,500 F1: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2026 Filed Aug 25, 2026 23:09 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 1,734 | $3.86 | $6,687.86 |
DisclosureSEC source: 0001869194-26-000011 · wk-form4_1787699362.xml · nonDerivative · entry 4 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 367,456 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 23:09 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 2,430 | $3.86 | $9,372.27 |
DisclosureSEC source: 0001869194-26-000011 · wk-form4_1787699362.xml · nonDerivative · entry 3 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 369,190 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 23:09 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 3,089 | $3.86 | $11,913.96 |
DisclosureSEC source: 0001869194-26-000011 · wk-form4_1787699362.xml · nonDerivative · entry 2 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,620 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 23:09 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 3,486 | $3.86 | $13,445.15 |
DisclosureSEC source: 0001869194-26-000011 · wk-form4_1787699362.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,709 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:01 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionStock Option (Right to Buy) · Derivative | 31,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001869194-26-000008 · wk-form4_1782158491.xml · derivative · entry 3 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F3 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:01 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 81,898 | $5.99 | $490,487.12 |
DisclosureSEC source: 0001869194-26-000008 · wk-form4_1782158491.xml · nonDerivative · entry 2 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 378,195 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F2 · price: Transaction was executed in multiple trades in prices ranging from $5.97 to $6.0086, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:01 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionCommon Stock | 31,000 | $0.99 | $30,690.00 |
DisclosureSEC source: 0001869194-26-000008 · wk-form4_1782158491.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 460,093 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:09 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 1,418 | $6.27 | $8,887.32 |
DisclosureSEC source: 0001869194-26-000006 · wk-form4_1779480546.xml · nonDerivative · entry 4 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 429,093 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:09 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 1,911 | $6.27 | $11,977.19 |
DisclosureSEC source: 0001869194-26-000006 · wk-form4_1779480546.xml · nonDerivative · entry 3 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,511 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:09 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 2,157 | $6.27 | $13,519.00 |
DisclosureSEC source: 0001869194-26-000006 · wk-form4_1779480546.xml · nonDerivative · entry 2 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 432,422 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:09 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 1,503 | $6.27 | $9,420.05 |
DisclosureSEC source: 0001869194-26-000006 · wk-form4_1779480546.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,579 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 01:47 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 984 | $5.71 | $5,622.38 |
DisclosureSEC source: 0001610717-26-000062 · form4.xml · nonDerivative · entry 2 Williams Laura A · CIK 0001869194 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 436,082 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 01:47 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 7,192 | $5.87 | $42,181.08 |
DisclosureSEC source: 0001610717-26-000062 · form4.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 437,066 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| January 23, 2026 Filed Jan 26, 2026 21:23 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 124,040 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001610717-26-000020 · form4.xml · derivative · entry 2 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,040 Underlying: Common Stock · 124,040 shares Expires 2036-01-23 F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 23, 2026, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| January 23, 2026 Filed Jan 26, 2026 21:23 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 82,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000020 · form4.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,258 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 23:59 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionStock Option (Right to Buy) · Derivative | 0 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001869194-26-000002 · wk-form4_1768003182.xml · derivative · entry 3 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 50,000 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 23:59 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 50,000 | $6.98 | $348,900.00 |
DisclosureSEC source: 0001869194-26-000002 · wk-form4_1768003182.xml · nonDerivative · entry 2 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 361,563 F1 · price: This transaction was executed in multiple trades in prices ranging from $6.97 to $7.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Reflects the adjusted total which includes the purchase of 1,667 shares under the Ardelyx Employee Stock Purchase Plan in August 2025. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 23:59 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionCommon Stock | 50,000 | $0.99 | $49,500.00 |
DisclosureSEC source: 0001869194-26-000002 · wk-form4_1768003182.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 409,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 21:35 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 6,426 | $5.54 | $35,580.12 |
DisclosureSEC source: 0001610717-25-000394 · form4.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 359,896 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 23:30 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001628280-25-041339 · wk-form4_1756423821.xml · derivative · entry 4 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 50,000 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 23:30 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 30,000 | $6.12 | $183,630.00 |
DisclosureSEC source: 0001628280-25-041339 · wk-form4_1756423821.xml · nonDerivative · entry 3 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 366,322 F1 · price: This transaction was executed in multiple trades in prices ranging from $6.04 to $6.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 23:30 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 50,000 | $6.12 | $306,050.00 |
DisclosureSEC source: 0001628280-25-041339 · wk-form4_1756423821.xml · nonDerivative · entry 2 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 396,322 F1 · price: This transaction was executed in multiple trades in prices ranging from $6.04 to $6.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 23:30 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionCommon Stock | 50,000 | $0.99 | $49,500.00 |
DisclosureSEC source: 0001628280-25-041339 · wk-form4_1756423821.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 446,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2025 Filed Aug 26, 2025 01:13 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 6,261 | $5.93 | $37,138.37 |
DisclosureSEC source: 0001628280-25-041139 · wk-form4_1756170821.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 396,322 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| May 20, 2025 Filed May 23, 2025 01:55 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 6,421 | $4.08 | $26,206.67 |
DisclosureSEC source: 0001628280-25-027433 · wk-form4_1747965323.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402,583 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:06 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 157,700 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0001628280-25-008810 · wk-form4_1740697572.xml · derivative · entry 2 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,700 Underlying: Common Stock · 157,700 shares Expires 2035-02-25 F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of February 25, 2025, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:06 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 105,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-008810 · wk-form4_1740697572.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 409,004 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 23:56 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 4,941 | $5.62 | $27,783.24 |
DisclosureSEC source: 0001628280-25-007234 · wk-form4_1740182178.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,804 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: Transaction was executed in multiple trades in prices ranging from $5.601611 to $5.625428, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 23:37 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 7,366 | $4.79 | $35,316.29 |
DisclosureSEC source: 0001628280-24-049057 · wk-form4_1732318656.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308,745 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Reflects the adjusted total which includes the purchase of 1,371 shares under the Ardelyx Employee Stock Purchase Plan in August 2024. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 22:28 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 7,412 | $5.86 | $43,436.54 |
DisclosureSEC source: 0001628280-24-038296 · wk-form4_1724365676.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 314,740 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 22:29 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001628280-24-027351 · wk-form4_1717799368.xml · derivative · entry 4 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 5, 2023, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 22:29 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 100,000 | $7.13 | $712,500.00 |
DisclosureSEC source: 0001628280-24-027351 · wk-form4_1717799368.xml · nonDerivative · entry 3 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 322,152 F1 · price: This transaction was executed in multiple trades in prices ranging from $7.11 to $7.145, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 22:29 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 45,000 | $7.12 | $320,580.00 |
DisclosureSEC source: 0001628280-24-027351 · wk-form4_1717799368.xml · nonDerivative · entry 2 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 422,152 F1 · price: This transaction was executed in multiple trades in prices ranging from $7.11 to $7.145, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 22:29 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionCommon Stock | 100,000 | $2.75 | $275,000.00 |
DisclosureSEC source: 0001628280-24-027351 · wk-form4_1717799368.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 467,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:21 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 4,794 | $7.81 | $37,445.93 |
DisclosureSEC source: 0001628280-24-024955 · wk-form4_1716495670.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 367,152 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Reflects the adjusted total which includes the purchase of 1,757 shares under the Ardelyx Employee Stock Purchase Plan in February 2024. Read SEC document |
| May 03, 2024 Filed May 7, 2024 20:48 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001610717-24-000230 · form4.xml · derivative · entry 3 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,000 Underlying: Common Stock · 30,000 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| May 03, 2024 Filed May 7, 2024 20:48 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 39,949 | $8.35 | $333,574.15 |
DisclosureSEC source: 0001610717-24-000230 · form4.xml · nonDerivative · entry 2 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 370,189 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| May 03, 2024 Filed May 7, 2024 20:48 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionCommon Stock | 30,000 | $0.99 | $29,700.00 |
DisclosureSEC source: 0001610717-24-000230 · form4.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 410,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:56 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 4,803 | $8.75 | $42,008.48 |
DisclosureSEC source: 0001610717-24-000080 · form4.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,138 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:39 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 152,127 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001628280-24-001692 · wk-form4_1705613951.xml · derivative · entry 2 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,127 Underlying: Common Stock · 152,127 shares Expires 2034-01-16 F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 16, 2024, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:39 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 118,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-001692 · wk-form4_1705613951.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 384,941 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 22:22 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 2,581 | $4.36 | $11,258.84 |
DisclosureSEC source: 0001628280-23-039907 · wk-form4_1700691709.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,191 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Reflects the adjusted total which includes the purchase of 1,933 shares under the Ardelyx Employee Stock Purchase Plan in August 2023. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 22:30 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 25,000 | $4.00 | $99,997.50 |
DisclosureSEC source: 0001628280-23-039528 · wk-form4_1700260214.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,839 F1 · price: This transaction was executed in multiple trades in prices ranging from $3.97 to $4.045, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 20:46 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 2,591 | $3.55 | $9,202.71 |
DisclosureSEC source: 0001628280-23-030412 · wk-form4_1692823583.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,839 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $3.5135 to $3.551843, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 23:22 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 25,000 | $3.35 | $83,632.50 |
DisclosureSEC source: 0001628280-23-023956 · wk-form4_1688080938.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,430 F1 · price: This transaction was executed in multiple trades in prices ranging from $3.331 to $3.365, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 23, 2023 Filed May 25, 2023 12:51 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 2,583 | $3.65 | $9,436.22 |
DisclosureSEC source: 0001104659-23-064386 · tm2316962-1_4seq1.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 319,430 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Reflects the adjusted total which includes the purchase of 3,000 shares under the Ardelyx Employee Stock Purchase Plan in February 2023. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 22:41 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 3,187 | $3.00 | $9,564.19 |
DisclosureSEC source: 0001567619-23-003774 · doc1.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,013 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 21:23 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 351,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001567619-23-000640 · doc1.xml · derivative · entry 2 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,000 Underlying: Common Stock · 351,000 shares Expires 2033-01-05 F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 5, 2023, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 21:23 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 78,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000640 · doc1.xml · nonDerivative · entry 1 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,200 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 21:13 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 1,193 | $1.95 | $2,325.51 |
DisclosureSEC source: 0001567619-22-020844 · doc1.xml · nonDerivative · entry 3 Williams Laura A · CIK 0001869194 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,200 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.